[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The study is an open label, single-arm study designed to evaluate the safety and diagnostic
performance of [18F]FLOR (FC303) PET/CT imaging to determine the presence or absence of
metastatic prostate cancer. .
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins